Perpetual Ltd Buys New Stake in Humana Inc. $HUM

Key Points

• Perpetual Ltd has acquired 2,006 shares of Humana Inc. in Q2, valued at approximately $490,000, according to its latest SEC filing.
• Institutional investors own 92.38% of Humana's stock, with significant recent stake increases from firms like Vanguard Group and AQR Capital Management.
• Humana reported $6.27 EPS for the latest quarter, missing expectations, but had a quarterly revenue of $32.39 billion, exceeding analysts' expectations.

Perpetual Ltd bought a new stake in Humana Inc. (NYSE:HUM - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,006 shares of the insurance provider's stock, valued at approximately $490,000.

Several other hedge funds have also recently made changes to their positions in HUM. Cary Street Partners Investment Advisory LLC increased its position in shares of Humana by 63.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock valued at $31,000 after acquiring an additional 46 shares during the period. Riverview Trust Co acquired a new position in shares of Humana in the 1st quarter valued at $34,000. Garde Capital Inc. purchased a new stake in Humana in the first quarter valued at $36,000. Zions Bancorporation National Association UT acquired a new stake in Humana during the 1st quarter worth about $37,000. Finally, Whipplewood Advisors LLC grew its position in Humana by 639.1% during the 1st quarter. Whipplewood Advisors LLC now owns 170 shares of the insurance provider's stock worth $45,000 after purchasing an additional 147 shares during the period. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Price Performance

HUM stock traded up $5.43 during mid-day trading on Monday, reaching $258.09. The company's stock had a trading volume of 1,926,931 shares, compared to its average volume of 1,845,160. The company's 50 day moving average is $268.56 and its two-hundred day moving average is $257.24. The stock has a market cap of $31.04 billion, a PE ratio of 19.81, a P/E/G ratio of 1.48 and a beta of 0.44. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $324.38.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The business had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The company's revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. Equities research analysts expect that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, September 26th. Humana's payout ratio is 27.17%.

Analysts Set New Price Targets

HUM has been the topic of several analyst reports. Wall Street Zen downgraded Humana from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Sanford C. Bernstein increased their price target on Humana from $269.00 to $341.00 and gave the stock an "outperform" rating in a research report on Friday, September 5th. Wells Fargo & Company cut their price target on Humana from $348.00 to $344.00 and set an "overweight" rating on the stock in a research report on Thursday, August 14th. Robert W. Baird cut their price target on Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a research report on Friday, July 25th. Finally, Royal Bank Of Canada increased their price target on Humana from $283.00 to $322.00 and gave the stock an "outperform" rating in a research report on Thursday, August 21st. Seven research analysts have rated the stock with a Buy rating and seventeen have given a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $289.50.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.